GlobeNewswire Inc.··NaAnteris Secures $320M to Advance DurAVR Trial as CMS Reimbursement Clears Path to U.S. Expansion
Anteris raises $320M, begins U.S. patient enrollment for DurAVR heart valve trial, secures CMS reimbursement with $28.7M quarterly cash burn.
AVRcapital raisePARADIGM Trial